CSSI - Costas, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0300
-0.0050 (-14.29%)
At close: 1:05PM EST
Stock chart is not supported by your current browser
Previous Close0.0350
Open0.0300
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0300 - 0.0300
52 Week Range0.0130 - 0.2200
Volume15,600
Avg. Volume28,871
Market Cap428,565
Beta (3Y Monthly)-0.93
PE Ratio (TTM)N/A
EPS (TTM)-0.0780
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Atlas Nanotech Targets the World’s Largest Consumer Health Products Companies to License the FirstEver Nanotechnology Vitamin A (Retinol) Based Crystalline Eye Drop

    GUADALAJARA, Mexico, Nov. 14, 2019 (GLOBE NEWSWIRE) -- vía OTC PR WIRE – Costas, Inc. (CSSI) DBA/Atlas Nanotech, (the “Company”) is currently in discussions to license their proprietary nanotechnology vitamin a (retinol) based crystalline eye drops known under the trade name “NANO CLEAR A”, to the leading eye drop manufactures, by licensing Nano Clear A to existing top tier eye drop manufactures it will allow the product to be widely used at a rapid pace. Atlas Nanotech’s business model is to develop and patent unique nanotechnology products. The Company’s scientific team is confident in its ability to license existing products and continue to develop additional nanotechnology products that the company will license to some of the world’s leading biotechnology, pharmaceutical and consumer products manufacturers.

  • Atlas Nanotech Announces the Successful Development of the First Ever ‘Over The Counter’ Vitamin ‘A’ (Retinol) Eye-Drops
    GlobeNewswire

    Atlas Nanotech Announces the Successful Development of the First Ever ‘Over The Counter’ Vitamin ‘A’ (Retinol) Eye-Drops

    GUADALAJARA, México, Sept. 23, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Costas Inc. (CSSI) DBA Atlas Nanotech adds another unique nanotechnology medical product to its portfolio. The product to be sold under the trade name “NANO CLEAR A” will compete with products in the treatment of dry eye disease, a $1.8-billion market in the U.S. The development represents the culmination of research initiated by Dr. Aldo Oregon Miranda, an ophthalmologist surgeon and member of the scientific advisory board of Atlas Nanotech, in collaboration with Professor David De La Mora, Atlas’ chairman.

  • GlobeNewswire

    Atlas Nanotech Opens First Revenue Stream

    GUADALAJARA, Mexico, July 31, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – CSSI (Costas Inc.), DBA Atlas Nanotech, today memorialized an agreement with Laboratorios Gem S.A. de C.V. of Mexico City gemlabs.mx. The contract calls for Atlas to sell stabilized and functionalized silver nanoparticles to Gem Labs for use in the manufacture of one of Gem Labs proprietary products. The contract is understood as a first act of trade between the parties and goes on to define initial terms of a licensing agreement for the use and exploitation of Nanogasa (nanogasa.com), a patented development of Atlas Nanotech.

  • GlobeNewswire

    Atlas Nanotech of Guadalajara to begin alliance with European Nano Medical S.R.O.

    GUADALAJARA, Mexico, June 27, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – CSSI (Costas Inc.) DBA Atlas Nanotech has entered an accord with Nano Medical S.R.O. of the Czech Republic. Atlas has successfully completed the submission of documentation and payment for two unique nanotechnology products through the Mexican regulator COFEPRIS. Initially, Atlas plans to distribute Nano Medical S.R.O.’s products in Mexico and, eventually, throughout Latin America, while Nano Medical S.R.O will distribute Atlas Nanotech’s products in Europe.

  • GlobeNewswire

    COSTAS Inc. (CSSI) Acquires Medical Nanotechnology Company, Appoints New Management and Board Members

    LAS VEGAS, June 06, 2019 (GLOBE NEWSWIRE) -- via NetworkWire – COSTAS,Inc.  (CSSI), announces its acquisition of Atlas Nanotech (formerly known as Nano Creaciones SAPI de CV) in an all-stock transaction that marks the Company’s entrance into the multi-billion-dollar global nanomedicine marketplace. The terms of the share exchange agreement include the appointment of new managing officers and a new board of directors, the resignation of COSTA’s current officers and board of directors and the retirement of 12,660,000 shares. The principles of Atlas are receiving 25,000,000 shares of CSSI subject to a lock-up agreement with staggered release of shares over a 2-year period.

  • GlobeNewswire

    Costas, Inc. Anticipates Recently Signed Farm Bill to Have Significant Impact on CSSI Initiatives in Hemp, Cannabis Industry

    NEW YORK, Dec. 31, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Costas Inc. (OTC MARKETS:CSSI) (CSSI or “the Company) is pleased to announce that, in the wake of the $867 billion 2018 Farm Bill having been signed into Law, the Company is entering the Cannabis industry which will include multiple acquisitions and operations in the sector to include extraction, processing, marketing and distribution.  The Company Board has approved purchasing of extraction equipment and partnerships with select cultivators in processing multiple product lines. “The 2018 Farm Bill includes an amendment that removes hemp from the list of controlled substances under federal law. This legalizes, federally, hemp cultivation which could lead to a potential of additional 1 million jobs in the United States for 2019.  Our team agrees that the industry is poised for seismic growth and Costas will position itself strategically for meaningful participation in the market.